Dr Reddy's Lenacapavir USFDA Nod: Twice-Yearly HIV Prevention Shot, Access Deal, and What It Means, Explained

Dr Reddy's Laboratories has received tentative approval from the US Food and Drug Administration (USFDA) for a long-acting injectable form of lenacapavir, used as pre-exposure prophylaxis (PrEP) against HIV. The Hindu Business Line, in a Hyderabad report updated at 9:07 pm IST on 2 November 2026, said the injection is to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg.

The approval sits under the US FDA's President's Emergency Plan for AIDS Relief (PEPFAR) programme. It is tied to a Gilead Sciences voluntary licence and to a $40 per person per year access plan for 120 countries. It is not, on the reporting used here, a commercial launch in the United States, and these reports do not give an India launch date.

This is an explainer of those reports. It is not medical advice and not a recommendation to start, stop, or switch any medicine.

The 60-second version

• The nod: Tentative USFDA approval for long-acting injectable lenacapavir for PrEP, reported by The Hindu Business Line on 2 November 2026.
• Who it is for, in the label the reports describe: Adults and adolescents weighing at least 35 kg, to reduce the risk of sexually acquired HIV-1.
• Which pathway: The US FDA's PEPFAR programme. Reuters said this is a route toward sales in many low- and middle-income countries, not yet in the United States.
• The deal: Gilead voluntary licence in October 2024. A September 2025 agreement with Unitaid, Wits RHI and CHAI. Access priced at $40 per person per year across 120 countries in that licence.
• The company's line: Deepak Sapra, CEO, API and Services, said the FDA approval validates the work and brings the twice-yearly option closer for people in low- and middle-income countries.
• Timing: First supplies expected by the end of 2026. Broader rollout across eligible countries in 2027. No India date in these reports.
• The share: CNBC-TV18 said the BSE close on 2 November was Rs 1,340.25, down 0.74 percent. Market reports described an early rise the same day. That close is context, not a verdict this page is drawing on the approval.

What the tentative approval covers

Business Line said Dr Reddy's received tentative USFDA approval for its long-acting injectable lenacapavir for PrEP. CNBC-TV18, in a report timestamped late on 2 November, described the same decision and added the weight in both units used in the company material: adults and adolescents weighing at least 77 pounds (35 kg).

Both reports said the approval was granted under the PEPFAR programme. CNBC-TV18 said it paves the way for access across 120 countries outside the US under an existing voluntary licensing agreement.

The Hindu Business Line called the decision an important milestone for the Hyderabad-based company's Public Health Access portfolio, and said it reflects Dr Reddy's capabilities in developing and manufacturing complex medicines.

What "tentative" means, and what it does not

Tentative approval is the word the company, Business Line, CNBC-TV18 and Unitaid all use. It is a specific designation, and the reports draw a line between this pathway and a sale on the US commercial market.

Unitaid, which is part of the access agreement, said tentative approval is the FDA's standard designation for a generic while the originator remains under patent, and that it enables procurement by the US government. Reuters, as carried by Yahoo on 2 November, said Dr Reddy's announcement paves the way for sales in many low- and middle-income countries, though not yet in the United States.

Read together, those accounts say the generic has cleared the bar the FDA uses for this PEPFAR-linked review, while the originator patent still stands in the way of a full US marketing approval. The point of the nod, as the company and the wire describe it, is generic access in the countries covered by Gilead's voluntary licence. The branded product's US commercial market is a separate question. This article does not treat the tentative nod as permission to sell Dr Reddy's lenacapavir in the United States.

Business Standard added a further limit on how quickly people actually receive the drug. It reported that wider availability will also depend on further steps, including World Health Organization prequalification and national regulatory approvals in individual markets. That is a reported dependency. It is not a finding, in the sources used here, that WHO has or has not prequalified the product, and it is not an Indian regulator's decision. No India launch date appears in the Business Line, CNBC-TV18, or company-release accounts this page is using.

The Gilead licence and the $40 price

Business Line set out two earlier steps that the approval builds on.

In October 2024, Gilead Sciences granted Dr Reddy's a voluntary licence. In September 2025, Dr Reddy's reached an agreement with Unitaid, the Wits Reproductive Health and HIV Institute (Wits RHI) and the Clinton Health Access Initiative (CHAI). Business Line said that agreement was to support product development, accelerate the regulatory pathway, and enable access to injectable lenacapavir at $40 per person per year across 120 countries in Gilead's voluntary licence.

CNBC-TV18 reported the same price and the same 120-country coverage, and said Gilead granted the licence to Dr Reddy's in October 2024. The $40 figure is the access price in that agreement, as those reports describe it. It is not a price this article is quoting for the United States, and it is not an Indian retail price. None of these reports states one.

Deepak Sapra, Chief Executive Officer, API and Services, Dr. Reddy's Laboratories, said in the company release, as carried by CNBC-TV18 and in the key sentence by Business Line:

"Developing and manufacturing a complex long-acting injectable like lenacapavir at an affordable price required strong scientific capabilities and manufacturing expertise to address an urgent access need. The US FDA approval validates that work and brings us a significant step closer to making this twice-yearly HIV prevention option available to people across low- and middle-income countries."

What lenacapavir is, in the company's words

Business Line described the medicine from the company release, and this section stays inside that description.

It said lenacapavir is a first-in-class, long-acting HIV-1 capsid inhibitor with a novel mechanism of action. The multi-stage mechanism is distinguishable from other currently approved classes of antiviral agents. While most antivirals act on one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle. Business Line said it has no known cross-resistance exhibited in vitro to other existing drug classes.

The paper also said long-acting lenacapavir, given twice a year, is an additional prevention option for people who may find a more frequent PrEP schedule hard to stay on. HIV, it said, remains a significant global public health challenge, with gaps in access to and uptake of effective prevention.

Those sentences are the company's and the paper's framing. They are not a dosing guide, an efficacy claim this desk has checked against a trial paper, or advice for any reader. Decisions about PrEP belong with a clinician and the local regulator.

When supplies are expected

Business Line's headline summary said the first supplies are expected to reach people by the end of 2026, with a broader rollout across eligible countries expected in 2027. CNBC-TV18's wording, attributed to the company, was that first supplies are expected to reach countries before the end of 2026, with broader availability across eligible countries in 2027.

Both point to the same window: some supply in 2026, a wider rollout in 2027, inside the set of countries the licence covers. Neither report names India as a 2026 or 2027 launch market. This page will not add a date the sources do not give.

The share price on 2 November

CNBC-TV18 said shares of Dr Reddy's Laboratories ended at Rs 1,340.25, down Rs 9.95, or 0.74 percent, on the BSE. That is the close this article is using. It is not adding other price levels.

Market reports of the session described the shares as higher in early trade before that lower close. The approval stories used here landed late. Business Line was updated at 9:07 pm IST, and CNBC-TV18's piece was published after 11:30 pm IST. The cash market was already shut. The 0.74 percent decline is the day's BSE print. It is not presented here as the market's reaction to the USFDA news.

What to watch next

1. First supplies by the end of 2026, and whether the broader rollout across eligible licence countries follows in 2027, as Business Line and the company described.
2. Whether the $40 per person per year price is the price at which supply actually moves in the 120 countries covered by the Gilead licence.
3. The steps Business Standard flagged after tentative approval: WHO prequalification and national regulatory approvals. These reports do not state an India launch date.
4. The US line Reuters drew: sales in many low- and middle-income countries, and not yet in the United States. A full commercial approval for the US market would be a different announcement.
5. The next session's share trade, after a 2 November BSE close of Rs 1,340.25, down 0.74 percent, in a session that ended before the evening reports of the approval.

The tentative nod is a regulatory step on a generic-access path the company has been building since the 2024 Gilead licence. The 2026 supply window, the $40 price, and the national approvals still have to happen before that path is a product in a clinic.

---

This article is for information only. It is not medical advice and not investment advice. The tentative USFDA approval, the PEPFAR programme, the 35 kg threshold, the Deepak Sapra quote, the October 2024 Gilead licence, the September 2025 agreement with Unitaid, Wits RHI and CHAI, the $40 price, the 120 countries, the supply timeline, the Public Health Access milestone, and the description of lenacapavir are from The Hindu Business Line (updated 2 November 2026) and the company release as carried there and by CNBC-TV18. The BSE close of Rs 1,340.25, down 0.74 percent, is from CNBC-TV18. Early-trade descriptions are from market reports of the 2 November session. The "not yet in the United States" line is from Reuters, as carried by Yahoo. Unitaid's description of tentative approval is from its 2 November 2026 note. Business Standard reported that wider availability also depends on WHO prequalification and national regulatory approvals. No India launch date is stated in these reports.